Korea Acute Myocardial Infarction Registry (KAMIR-7)

March 9, 2026 updated by: Joo-Yong Hahn, Samsung Medical Center

A Multicentre Observational Study to Improve Long-term Prognosis in Korean Patients With Acute Myocardial Infarction (Korea Acute Myocardial Infarction Registry [KAMIR-7])

This multicentre observational registry study, the Korea Acute Myocardial Infarction Registry (KAMIR-7), aims to improve long-term prognosis in Korean patients with acute myocardial infarction (AMI) by establishing and operating a nationwide patient registry system. Participating hospitals across Korea, treating AMI patients, will contribute prospective clinical and health-related data. The registry system is web-based and designed to support various clinical and epidemiologic research initiatives, provide standardized data, and facilitate collaborative studies, including participation in international studies such as GRACE.

The primary objectives are:

  1. To establish and maintain a sustainable nationwide AMI patient registry to enable continuous collection of high-quality clinical data.
  2. To develop a Korean-specific AMI prognostic model by evaluating the applicability and discriminative power of existing foreign risk prediction models (e.g., GRACE score, TIMI score, PERSUIT model, ACTION score) using domestic patient data.
  3. To identify clinical and management factors significantly affecting AMI outcomes and model mortality risk using accessible clinical and initial presentation data, including total ischemic time (symptom-to-hospital and door-to-balloon time).
  4. To develop clinical and quality indicators to evaluate appropriateness of care and emergency management systems, incorporating patient transport, pre-hospital management, and hospital treatment timeliness.

Secondary objectives include:

  • To ensure sustainable patient enrollment and prospective follow-up systems that can support clinical and public health research.
  • To create a resource for future research on new antiplatelet agents, stents, or interventional strategies.
  • To provide data for nested case-control studies within the cohort, facilitating research on clinical characteristics, treatment courses, and outcomes in AMI patients.
  • To identify new prognostic factors influencing patient outcomes and establish guidelines appropriate for Korean clinical practice.
  • To address limitations of prior KAMIR studies, including short follow-up duration and limited heart failure-related data, and incorporate evolving treatment strategies, devices, and medications.

Through systematic data collection and networked collaboration, this study will enable comprehensive analyses of long-term outcomes in Korean AMI patients, contribute to evidence-based optimization of treatment strategies, support development of prognostic tools specific to the Korean population, and inform health policy and clinical guideline refinement. The registry will also foster research collaboration among hospitals, investigators, and international study networks to advance the understanding and management of AMI in Korea.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This is a multicenter, prospective, observational registry study of patients diagnosed with acute myocardial infarction (AMI) at participating hospitals across Korea. Patients are identified and enrolled from hospitals treating AMI nationwide. All data are entered into a web-based electronic case report form (eCRF) system and centrally managed, with no personally identifiable information collected.

Each patient is assigned a unique study identification number, separate from any hospital-specific patient ID, to ensure confidentiality. Data entry is performed by trained study coordinators following standardized procedures. The coordinators undergo professional training, and continuous monitoring of data entry practices, registration progress, and ongoing study operations is conducted. A core-lab coordinator visits each participating site and facilitates staff interactions and exchange work to minimize inter-site bias and ensure standardized, high-quality data collection. All collected measures are defined according to standardized definitions to maintain consistency across sites.

Follow-up data will be collected at 6, 12, 24, and 36 months after the index procedure.

Data Privacy and Security Measures All personally identifiable information, such as names, resident registration numbers, hospital numbers, addresses, email addresses, and phone numbers, will not be collected. Collected information is managed using a unique study number for each patient. The eCRF system is secured with account-specific login credentials and passwords. Access is restricted to study personnel authorized by the principal investigator.

The study database is regularly monitored to maintain data quality, and measures are in place to standardize data collection and minimize bias. Patient confidentiality is protected throughout the study, and all procedures comply with applicable regulations for data protection.

Research data will be stored for three years after the study completion according to the Bioethics Act. After the retention period, personal information will be destroyed in accordance with Article 16 of the Personal Information Protection Act Enforcement Decree.

Study Type

Observational

Enrollment (Estimated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • South Korea
      • Gwangju, South Korea
        • Chonnam National University Hospital
        • Contact:
      • Seoul, South Korea
        • Samsung Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Study participants are patients aged 19 years or older diagnosed with acute myocardial infarction who are enrolled at participating hospitals in Korea as part of the KAMIR-7 registry and followed for up to 3 years.

Description

Inclusion Criteria:

  • Age ≥ 19 years
  • Patients diagnosed with acute myocardial infarction (AMI) (either ST-segment elevation myocardial infarction [STEMI] or non-ST-segment elevation myocardial infarction [NSTEMI]), meeting both of the following:
  • Elevated cardiac troponin above the 99th percentile upper reference limit
  • Evidence of myocardial ischemia, as indicated by symptoms, electrocardiographic (ECG) changes, and/or imaging evidence

Exclusion Criteria:

- Patients who do not provide informed consent to participate in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major adverse cardiac events (MACE) during follow-up
Time Frame: 6, 12, 24, and 36 months after index procedure
MACE is defined as a composite endpoint of cardiovascular death, recurrent myocardial infarction, and coronary revascularization.
6, 12, 24, and 36 months after index procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Collaborators

The Korean Society of Cardiology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2031

Study Registration Dates

First Submitted

February 8, 2026

First Submitted That Met QC Criteria

February 8, 2026

First Posted (Actual)

February 13, 2026

Study Record Updates

Last Update Posted (Actual)

March 10, 2026

Last Update Submitted That Met QC Criteria

March 9, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SMC 2025-10-089-007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to make IPD publicly available.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction, Acute

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe